Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.

Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly A, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Sridharan A, Gueorguieva I, Girvan A, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Will B, Verma A.

Clin Cancer Res. 2019 Sep 3. pii: clincanres.1338.2019. doi: 10.1158/1078-0432.CCR-19-1338. [Epub ahead of print]

PMID:
31481511
2.
3.

Runx1 promotes murine erythroid progenitor proliferation and inhibits differentiation by preventing Pu.1 downregulation.

Willcockson MA, Taylor SJ, Ghosh S, Healton SE, Wheat JC, Wilson TJ, Steidl U, Skoultchi AI.

Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17841-17847. doi: 10.1073/pnas.1901122116. Epub 2019 Aug 20.

PMID:
31431533
4.

Misidentification of MLL3 and other mutations in cancer due to highly homologous genomic regions.

Bowler TG, Pradhan K, Kong Y, Bartenstein M, Morrone KA, Sridharan A, Kessel RM, Shastri A, Giricz O, Bhagat TD, Gordon-Mitchell S, Rohanizadegan M, Hooda L, Datt I, Przychodzen BP, Parmar S, Maqbool S, Maciejewski JP, Steidl U, Greally JM, Verma A.

Leuk Lymphoma. 2019 Jul 10:1-6. doi: 10.1080/10428194.2019.1630620. [Epub ahead of print]

PMID:
31288594
5.

HIV portends a poor prognosis in myelodysplastic syndromes.

Kaner JD, Thibaud S, Jasra S, Wang Y, Janakiram M, Sharma A, Sridharan A, Elias H, Polineni R, Assal A, Weiss L, Braunschweig I, Steidl U, Pradhan K, Shastri A, Chaitowitz M, Zingman B, Will B, Mantzaris I, Verma A.

Leuk Lymphoma. 2019 Jul 8:1-7. doi: 10.1080/10428194.2019.1633631. [Epub ahead of print]

PMID:
31282240
6.

Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy?

Piszczatowski RT, Steidl U.

Clin Cancer Res. 2019 Aug 15;25(16):4868-4870. doi: 10.1158/1078-0432.CCR-19-1481. Epub 2019 Jun 13.

PMID:
31196854
7.

U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies.

Smith MA, Choudhary GS, Pellagatti A, Choi K, Bolanos LC, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V, Kim S, Steidl U, Walter M, Fraser IDC, Kulkarni A, Salomonis N, Komurov K, Boultwood J, Verma A, Starczynowski DT.

Nat Cell Biol. 2019 May;21(5):640-650. doi: 10.1038/s41556-019-0314-5. Epub 2019 Apr 22.

8.

Transcriptional regulators CITED2 and PU.1 cooperate in maintaining hematopoietic stem cells.

Mattes K, Geugien M, Korthuis PM, Brouwers-Vos AZ, Fehrmann RSN, Todorova TI, Steidl U, Vellenga E, Schepers H.

Exp Hematol. 2019 May;73:38-49.e7. doi: 10.1016/j.exphem.2019.03.003. Epub 2019 Apr 13.

PMID:
30986495
9.

Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis.

Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo WL, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw KL, Bhattacharyya S, Bishop MR, Artz A, Thirman MJ, Moliterno A, Ji P, Levine RL, Godley LA, Steidl U, Bieker JJ, List AF, Saunthararajah Y, He C, Verma A, Wickrema A.

Cancer Discov. 2019 Jun;9(6):778-795. doi: 10.1158/2159-8290.CD-18-1138. Epub 2019 Apr 3.

PMID:
30944118
10.

PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma.

Chung EY, Mai Y, Shah UA, Wei Y, Ishida E, Kataoka K, Ren X, Pradhan K, Bartholdy B, Wei X, Zou Y, Zhang J, Ogawa S, Steidl U, Zang X, Verma A, Janakiram M, Ye BH.

Clin Cancer Res. 2019 Jun 15;25(12):3589-3601. doi: 10.1158/1078-0432.CCR-18-3033. Epub 2019 Mar 12.

PMID:
30862694
11.

Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma.

Shenoy N, Bhagat TD, Cheville J, Lohse C, Bhattacharyya S, Tischer A, Machha V, Gordon-Mitchell S, Choudhary G, Wong LF, Gross L, Ressigue E, Leibovich B, Boorjian SA, Steidl U, Wu X, Pradhan K, Gartrell B, Agarwal B, Pagliaro L, Suzuki M, Greally JM, Rakheja D, Thompson RH, Susztak K, Witzig T, Zou Y, Verma A.

J Clin Invest. 2019 Mar 4;130:1612-1625. doi: 10.1172/JCI98747. eCollection 2019 Mar 4.

12.

Publisher Correction: Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level.

Chen J, Kao YR, Sun D, Todorova TI, Reynolds D, Narayanagari SR, Montagna C, Will B, Verma A, Steidl U.

Nat Med. 2019 Mar;25(3):529. doi: 10.1038/s41591-018-0333-y.

PMID:
30568307
13.

Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level.

Chen J, Kao YR, Sun D, Todorova TI, Reynolds D, Narayanagari SR, Montagna C, Will B, Verma A, Steidl U.

Nat Med. 2019 Jan;25(1):103-110. doi: 10.1038/s41591-018-0267-4. Epub 2018 Dec 3. Erratum in: Nat Med. 2018 Dec 19;:.

14.

Inhibition of HIF1α Signaling: A Grand Slam for MDS Therapy?

Chen J, Steidl U.

Cancer Discov. 2018 Nov;8(11):1355-1357. doi: 10.1158/2159-8290.CD-18-1061.

PMID:
30385524
15.

Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.

Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya S, Lopez R, Pradhan K, Giricz O, Ravipati G, Wong LF, Cole S, Bhagat TD, Feld J, Dhar Y, Bartenstein M, Thiruthuvanathan VJ, Wickrema A, Ye BH, Frank DA, Pellagatti A, Boultwood J, Zhou T, Kim Y, MacLeod AR, Epling-Burnette PK, Ye M, McCoon P, Woessner R, Steidl U, Will B, Verma A.

J Clin Invest. 2018 Dec 3;128(12):5479-5488. doi: 10.1172/JCI120156. Epub 2018 Nov 5.

16.

Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.

Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB, Verma A, Steidl U, Will B.

Sci Transl Med. 2018 Sep 12;10(458). pii: eaas9563. doi: 10.1126/scitranslmed.aas9563.

PMID:
30209246
17.

Linking histone methylation, transcription rates, and stem cell robustness.

Wheat JC, Steidl U.

Haematologica. 2018 Jul;103(7):1093. doi: 10.3324/haematol.2018.196089. No abstract available.

18.

IL1RAP potentiates multiple oncogenic signaling pathways in AML.

Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debré I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E, Verma A, Gritsman K, Steidl U.

J Exp Med. 2018 Jun 4;215(6):1709-1727. doi: 10.1084/jem.20180147. Epub 2018 May 17.

19.

Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster.

Landgren O, Zeig-Owens R, Giricz O, Goldfarb D, Murata K, Thoren K, Ramanathan L, Hultcrantz M, Dogan A, Nwankwo G, Steidl U, Pradhan K, Hall CB, Cohen HW, Jaber N, Schwartz T, Crowley L, Crane M, Irby S, Webber MP, Verma A, Prezant DJ.

JAMA Oncol. 2018 Jun 1;4(6):821-827. doi: 10.1001/jamaoncol.2018.0509.

20.

Metabolic strugGLS after FLT3 inhibition in AML.

Taylor SJ, Steidl U.

Blood. 2018 Apr 12;131(15):1631-1632. doi: 10.1182/blood-2018-03-836338. No abstract available.

PMID:
29650728
21.

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.

Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao3003. doi: 10.1126/scitranslmed.aao3003.

22.

Dynamic Regulation of Long-Chain Fatty Acid Oxidation by a Noncanonical Interaction between the MCL-1 BH3 Helix and VLCAD.

Escudero S, Zaganjor E, Lee S, Mill CP, Morgan AM, Crawford EB, Chen J, Wales TE, Mourtada R, Luccarelli J, Bird GH, Steidl U, Engen JR, Haigis MC, Opferman JT, Walensky LD.

Mol Cell. 2018 Mar 1;69(5):729-743.e7. doi: 10.1016/j.molcel.2018.02.005.

23.

LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.

Cusan M, Cai SF, Mohammad HP, Krivtsov A, Chramiec A, Loizou E, Witkin MD, Smitheman KN, Tenen DG, Ye M, Will B, Steidl U, Kruger RG, Levine RL, Rienhoff HY Jr, Koche RP, Armstrong SA.

Blood. 2018 Apr 12;131(15):1730-1742. doi: 10.1182/blood-2017-09-807024. Epub 2018 Feb 16.

24.

Hispanic ethnicity is associated with younger age at presentation but worse survival in acute myeloid leukemia.

Darbinyan K, Shastri A, Budhathoki A, Helbig D, Snyder R, Pradhan K, Saleh-Esa J, Kornblum NS, Binder AF, Goel S, Janakiram M, Derman O, Gritsman K, Steidl U, Braunschweig I, Verma A, Mantzaris I.

Blood Adv. 2017 Oct 26;1(24):2120-2123. doi: 10.1182/bloodadvances.2017007013. eCollection 2017 Nov 14.

25.

Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer.

Anampa J, Haque T, Murakhovskaya I, Wang Y, Bachiashvili K, Papazoglu C, Pradhan K, Steidl UG, Sparano JA, Verma A.

Haematologica. 2018 Mar;103(3):e98-e102. doi: 10.3324/haematol.2017.181941. Epub 2017 Nov 30. No abstract available.

26.

STAT3 inhibition as a therapeutic strategy for leukemia.

Kanna R, Choudhary G, Ramachandra N, Steidl U, Verma A, Shastri A.

Leuk Lymphoma. 2018 Sep;59(9):2068-2074. doi: 10.1080/10428194.2017.1397668. Epub 2017 Nov 22. Review.

PMID:
29164994
27.

Pharmacological inhibition of the transcription factor PU.1 in leukemia.

Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, Gavathiotis E, Verma A, Will B, Boykin DW, Wilson WD, Poon GM, Steidl U.

J Clin Invest. 2017 Dec 1;127(12):4297-4313. doi: 10.1172/JCI92504. Epub 2017 Oct 30.

28.

Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia.

Reyna DE, Garner TP, Lopez A, Kopp F, Choudhary GS, Sridharan A, Narayanagari SR, Mitchell K, Dong B, Bartholdy BA, Walensky LD, Verma A, Steidl U, Gavathiotis E.

Cancer Cell. 2017 Oct 9;32(4):490-505.e10. doi: 10.1016/j.ccell.2017.09.001.

29.

Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways.

Bhattacharyya S, Pradhan K, Campbell N, Mazdo J, Vasantkumar A, Maqbool S, Bhagat TD, Gupta S, Suzuki M, Yu Y, Greally JM, Steidl U, Bradner J, Dawlaty M, Godley L, Maitra A, Verma A.

Genome Res. 2017 Nov;27(11):1830-1842. doi: 10.1101/gr.222794.117. Epub 2017 Oct 6.

30.

ZNF143 protein is an important regulator of the myeloid transcription factor C/EBPα.

Gonzalez D, Luyten A, Bartholdy B, Zhou Q, Kardosova M, Ebralidze A, Swanson KD, Radomska HS, Zhang P, Kobayashi SS, Welner RS, Levantini E, Steidl U, Chong G, Collombet S, Choi MH, Friedman AD, Scott LM, Alberich-Jorda M, Tenen DG.

J Biol Chem. 2017 Nov 17;292(46):18924-18936. doi: 10.1074/jbc.M117.811109. Epub 2017 Sep 12.

31.

Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.

Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes AM, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM, Mukherjee S, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG, Verma A.

Cancer Res. 2017 Sep 15;77(18):4846-4857. doi: 10.1158/0008-5472.CAN-17-0282. Epub 2017 Jul 6.

32.

Efficacy of ALK5 inhibition in myelofibrosis.

Yue L, Bartenstein M, Zhao W, Ho WT, Han Y, Murdun C, Mailloux AW, Zhang L, Wang X, Budhathoki A, Pradhan K, Rapaport F, Wang H, Shao Z, Ren X, Steidl U, Levine RL, Zhao ZJ, Verma A, Epling-Burnette PK.

JCI Insight. 2017 Apr 6;2(7):e90932. doi: 10.1172/jci.insight.90932.

33.

ETO2-GLIS2: A Chimeric Transcription Factor Drives Leukemogenesis through a Neomorphic Transcription Network.

Wheat JC, Steidl U.

Cancer Cell. 2017 Mar 13;31(3):307-308. doi: 10.1016/j.ccell.2017.02.015.

34.

A myeloid tumor suppressor role for NOL3.

Stanley RF, Piszczatowski RT, Bartholdy B, Mitchell K, McKimpson WM, Narayanagari S, Walter D, Todorova TI, Hirsch C, Makishima H, Will B, McMahon C, Gritsman K, Maciejewski JP, Kitsis RN, Steidl U.

J Exp Med. 2017 Mar 6;214(3):753-771. doi: 10.1084/jem.20162089. Epub 2017 Feb 23.

35.

Stem and progenitor cell alterations in myelodysplastic syndromes.

Shastri A, Will B, Steidl U, Verma A.

Blood. 2017 Mar 23;129(12):1586-1594. doi: 10.1182/blood-2016-10-696062. Epub 2017 Feb 3. Review.

36.

DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders.

Sato H, Wheat JC, Steidl U, Ito K.

Front Oncol. 2016 Aug 22;6:187. doi: 10.3389/fonc.2016.00187. eCollection 2016. Review.

37.

Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy.

Carvajal LA, Steidl U.

Cell Stem Cell. 2016 Jul 7;19(1):6-8. doi: 10.1016/j.stem.2016.06.005.

38.

Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S, Bhagat T, Bhattacharyya S, Assal A, Shastri A, Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U, Verma A.

Cancer Res. 2016 Aug 15;76(16):4841-4849. doi: 10.1158/0008-5472.CAN-15-3062. Epub 2016 Jun 10.

39.

Analysis of overall survival in a large multiethnic cohort reveals absolute neutrophil count of 1,100 as a novel prognostic cutoff in African Americans.

Mantzaris I, Yu Y, Msaouel P, Lam AP, Janakiram M, Friedman EW, Steidl U, Verma AK.

Oncotarget. 2016 Oct 18;7(42):67948-67955. doi: 10.18632/oncotarget.8996.

40.

High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort.

Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski JP, Braunschweig I, Verma A.

Leukemia. 2016 Aug;30(8):1793-5. doi: 10.1038/leu.2016.74. Epub 2016 Apr 29. No abstract available.

PMID:
27125205
41.

Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal.

Pietras EM, Mirantes-Barbeito C, Fong S, Loeffler D, Kovtonyuk LV, Zhang S, Lakshminarasimhan R, Chin CP, Techner JM, Will B, Nerlov C, Steidl U, Manz MG, Schroeder T, Passegué E.

Nat Cell Biol. 2016 Jun;18(6):607-18. doi: 10.1038/ncb3346. Epub 2016 Apr 25.

42.

Molecular Mechanism of Mutant CALR-Mediated Transformation.

Stanley RF, Steidl U.

Cancer Discov. 2016 Apr;6(4):344-6. doi: 10.1158/2159-8290.CD-16-0238.

43.

Ectopic DNMT3B expression delays leukemogenesis.

Stanley RF, Steidl U.

Blood. 2016 Mar 24;127(12):1525-6. doi: 10.1182/blood-2016-01-692137.

PMID:
27013212
44.

Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes.

Sundaravel S, Duggan R, Bhagat T, Ebenezer DL, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Torregroza I, Quenon T, Anastasi J, McGraw KL, Pellagatti A, Boultwood J, Yajnik V, Artz A, Le Beau MM, Steidl U, List AF, Evans T, Verma A, Wickrema A.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):E6359-68. doi: 10.1073/pnas.1516394112. Epub 2015 Nov 2.

45.

Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.

Li W, Morrone K, Kambhampati S, Will B, Steidl U, Verma A.

Leukemia. 2016 Mar;30(3):536-44. doi: 10.1038/leu.2015.297. Epub 2015 Oct 26. Review.

PMID:
26500138
46.

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.

Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J, Verma A, Steidl U.

Nat Chem Biol. 2015 Nov;11(11):878-86. doi: 10.1038/nchembio.1930. Epub 2015 Oct 5.

47.

Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia.

Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, da Silva Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Neriah DB, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W, Verma A, Steidl U.

Nat Med. 2015 Oct;21(10):1172-81. doi: 10.1038/nm.3936. Epub 2015 Sep 7.

48.

PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U.

Blood. 2015 Aug 27;126(9):1118-27. doi: 10.1182/blood-2014-12-618801. Epub 2015 Jul 13.

49.

Functionally relevant RNA helicase mutations in familial and sporadic myeloid malignancies.

Antony-Debré I, Steidl U.

Cancer Cell. 2015 May 11;27(5):609-11. doi: 10.1016/j.ccell.2015.04.013.

50.

Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.

Shih AH, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, Woods B, Wei C, Hatlen M, Baljevic M, Nimer SD, Tallman M, Paietta E, Cimmino L, Aifantis I, Steidl U, Mason C, Melnick A, Levine RL.

Cancer Cell. 2015 Apr 13;27(4):502-15. doi: 10.1016/j.ccell.2015.03.009.

Supplemental Content

Loading ...
Support Center